Viral suppression and immune recovery after antiretroviral therapy initiation in a Moroccan human immunodeficiency virus type 1-infected cohort: A retrospective analysis
Eurasian Journal of Medicine and Oncology · 28.05.2026 · 10 (3) · 025370388
DOI: 10.36922/ejmo025370388 ↗Kurz gefasst
Fachartikel in der Zeitschrift Eurasian Journal of Medicine and Oncology, online erschienen am 28.05.2026. Verfasst von Maryam Ahmina und 14 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Introduction
Morocco has made substantial progress in expanding human immunodeficiency virus (HIV) testing and treatment, yet longitudinal data on immuno-virologic outcomes remain limited.
Objective
We sought to define the clinical profile at presentation and analyze long-term immuno-virologic outcomes under expanding integrase inhibitor-based treatment.
Methods
We performed a retrospective analysis of patients with confirmed HIV-1 infection who initiated antiretroviral therapy at the Center of Virology, Infectious, and Tropical Diseases at the Military Training Hospital between 2017 and 2025. Demographic, clinical, immunological, and virological data were collected at baseline and throughout follow-up. Statistical analyses were conducted using the Statistical Package for Social Sciences software.
Results
Late presentation was common: 35.7% presented with Centers for Disease Control and Prevention stage C, and 41.5% had CD4 < 200 cells/μL. Women had higher baseline cluster of differentiation 4 (CD4) counts than men (416 vs. 250 cells/μL; p = 0.001), whereas men displayed higher viral loads (1.19 × 105 vs. 5.51 × 104 copies/mL; p = 0.005). Opportunistic infections remained substantial, including cytomegalovirus (16.5%), tuberculosis (12.5%), and toxoplasmosis (5.8%). First-line therapy was initially non-nucleoside reverse transcriptase inhibitor-based in half of the patients, but rapid national adoption of updated guidelines led to 93.8% receiving dolutegravir plus two nucleoside reverse transcriptase inhibitors at the last follow-up. Viral loads declined sharply within the first month, with most patients achieving and maintaining suppression from months 6–12 onward. CD4 counts rose from a median of 279 cells/μL at baseline to 560 at year 3, peaking at 610 at year 5 before stabilizing.
Conclusion
Morocco’s transition to dolutegravir-based antiretroviral therapy has produced durable virologic control and robust immune recovery. Persistent late diagnosis, sex-based disparities, and limited access to genotyping remain major obstacles. Strengthening early testing, expanding molecular monitoring, and enhancing differentiated care services will be essential to sustain national progress.
Zitieren
APA
Ahmina, M., Lamrak, N., Reggad, A., Tagajdid, M. R., Abi, R., Elqatni, M., Laraqi, A., Elkochri, S., Bouaiti, E., Addi, Y., Mchichi, B. E., Touil, N., Annaz, H. E., Khalid, E., & Lahlou, I. A. (2026). Viral suppression and immune recovery after antiretroviral therapy initiation in a Moroccan human immunodeficiency virus type 1-infected cohort: A retrospective analysis. Eurasian Journal of Medicine and Oncology, 10(3), 025370388. https://doi.org/10.36922/ejmo025370388
Vancouver
Ahmina M, Lamrak N, Reggad A, Tagajdid MR, Abi R, Elqatni M, et al. Viral suppression and immune recovery after antiretroviral therapy initiation in a Moroccan human immunodeficiency virus type 1-infected cohort: A retrospective analysis. Eurasian Journal of Medicine and Oncology. 2026;10(3):025370388. doi:10.36922/ejmo025370388
BibTeX
@article{Ahmina2026,
author = {Ahmina, Maryam and Lamrak, Nada and Reggad, Ahmed and Tagajdid, Mohamed Rida and Abi, Rachid and Elqatni, Mohamed and Laraqi, Abdelilah and Elkochri, Safae and Bouaiti, Elarbi and Addi, Youssef and Mchichi, Bouchra El and Touil, Nadia and Annaz, Hicham El and Khalid, Ennibi and Lahlou, Idriss Amine},
title = {Viral suppression and immune recovery after antiretroviral therapy initiation in a Moroccan human immunodeficiency virus type 1-infected cohort: A retrospective analysis},
journal = {Eurasian Journal of Medicine and Oncology},
year = {2026},
volume = {10},
number = {3},
pages = {025370388},
doi = {10.36922/ejmo025370388}
}
EUVIMED